Lipocine (NASDAQ:LPCN) Shares Cross Below 200 Day Moving Average – Should You Sell?

Lipocine Inc. (NASDAQ:LPCN) shares crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.10 and traded as low as $2.09. Lipocine shares last traded at $2.14, with a volume of 29,153 shares traded.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Weiss Ratings cut shares of Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 18th. HC Wainwright reaffirmed a “neutral” rating on shares of Lipocine in a research note on Monday, April 6th. Finally, Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $15.00.

Lipocine Trading Up 2.9%

The company has a market capitalization of $17.63 million, a PE ratio of -1.14 and a beta of 0.44. The firm has a fifty day moving average of $2.29 and a two-hundred day moving average of $5.10.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.16 million. Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%. On average, equities analysts expect that Lipocine Inc. will post -1.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new position in shares of Lipocine in the third quarter worth $41,000. Geode Capital Management LLC grew its holdings in Lipocine by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after acquiring an additional 1,374 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Lipocine by 3.6% in the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after acquiring an additional 1,300 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Lipocine in the fourth quarter valued at about $85,000. Finally, Persistent Asset Partners Ltd purchased a new position in shares of Lipocine in the fourth quarter valued at about $567,000. Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.